Merus Announces Financial Results for the Second Quarter and Provides Business Update
Retrieved on:
Monday, August 8, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Betta, Trial of the century, Prostate cancer, ASCO, RECIST, Zeno, GLOBE, ORR, Annual general meeting, Clinical trial, NRG1, Non-small-cell lung carcinoma, IND, Achievement, HER2, Biologics license application, Cancer, Income, NSCLC, Pancreas, Patient, Neck, Pancreatic cancer, Program, HER3, Castration, Safety, Collaboration, Peto, Research, Chlorine, Head, AstraZeneca, Afatinib, Agreement, Food, Pharmaceutical industry, Health insurance, Dietary supplement, Cryptocurrency, Meru Networks, Osimertinib, Lilly, Incyte
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2022 and provided a business update.
Key Points:
- We believe the favorable safety profile of Zeno may also allow for future, potential benefit in combination with other cancer therapies.
- Details of the eNRGy trial can be found at www.ClinicalTrials.gov and Merus trial website at www.nrg1.com ,or by calling 1-833-NRG-1234.
- As of June 30, 2022, Merus had $396.8 million cash and cash equivalents sufficient to fund company operations beyond 2024.
- We ended the second quarter with cash, cash equivalents and marketable securities of $396.8 million compared to $430.7 million at December 31, 2021.